http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Purification and Characterization of Recombinant Murine Endostatin in E. coli
You, Weon-Kyoo,So, Seung-Ho,Lee, Hyosil,Park, Sun-Young,Yoon, Mi-Ran,Chang, Soo-Ik,Kim, Hyun-Kyung,Joe, Young-Ae,Hong, Yong-Kil,hung, Soo-Il 가톨릭대학교 2000 Bulletin of The Catholic Research Institutes of Me Vol.28 No.-
Endostatin, a carboxyl-terminal fragment of collagen X VIII is known as an anti-angiogenic agent, that specifically inhibits the proliferation of endothelial cell and the growth of several primary tumor. We report here the purification and characteriztion of recombinant murine endostatin (rmEndostain) which was expressed in a prokaryotic expression system. This rmEndostatin has similar physiochemical properties of Yeast-produced recombinant endostatin, and it also specifically inhibits the proliferation and migration of bovine capillary endothelial cells stimulated by basic fibroblast growth factor. The biological activity of rmEndostatin was also shown by its anti-angiogenic ability on the chorioallantoc membrane of chick embryo in vivo. In this article we demonstrate the refolding and purification of rmEndostatin expressed suing E. coli system, to a biologically active and soluble from. In addition, these results confirm the activity of endostain as a potent anti-angiogenic agent. (Experimental and Molecular Medicine 31(4):197-202, 1999)
Development and application of a bispecific antibody penetrating the blood-brain-barrier (BBB)
Weon-Kyoo YOU 한국생물공학회 2021 한국생물공학회 학술대회 Vol.2021 No.10
One of major challenges to develop effective therapeutics for neurodegenerative diseases is due to lack of the ability to penetrate Blood-Brain-Barrier (BBB) rather than lack of potency or efficacy of therapeutics. In order to overcome this hurdle, ABL Bio has developed a bispecific platform (Grabody-BTM) that can improve BBB-penetrating activity through the receptor-mediated transcytosis (RMT) pathway in the brain endothelial cells. The most advanced development program using this platform is ABL301, a bispecific antibody binding to aggregated alpha-synuclein as well as RMT target. ABL301 is being developed for the treatment of Parkinson’s disease (PD) via specific binding against alpha-synuclein, a main pathological aggregate in the brain of PD patients. ABL301’s alpha-synuclein binding moiety is highly specific for aggregated form with no cross-reactivity against other synuclein homologs. In addition, ABL301 has shown a better in vivo efficacy in preclinical animal models of PD via improved BBB-penetrating ability compared to its parental alpha-synuclein-binding monoclonal antibody. ABL301 could be developed as a potent first-in-class therapeutic antibody for the treatment of synucleinopathy with improved BBB penetration. ABL Bio’s bispecific platform (Grabody-BTM) can be also used and applied for the development of other biologics to treat different neurodegenerative diseases.